Upcoming Events

2018 Annual Meeting of Stockholders

Dec 18, 2018 • 10:00am EST

View All Events

Latest Financial Results

Q1 2019

Quarter Ended Oct 31, 2018

Latest Annual Filing

Fiscal Year Ended Jul 31, 2018

View Filing

Stock Information

Company Overview

OncoSec Medical Incorporated is a biopharmaceutical company developing its investigational immunotherapy, TAVO, for the treatment of cancer. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of TAVO have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating TAVO for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate TAVO in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.

Investor Presentation

Investor Presentation

Download Investor Presentation

Leadership

Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information

Company

OncoSec Medical Incorporated
3565 General Atomics Ct.
San Diego, CS 92121

Investor Relations

T: 855-ONCOSEC (855-662-6732)
investors@oncosec.com

Transfer Agent

Nevada Agency and Transfer Company
50 W. Liberty St.
Suite 880
Reno, NV 89501
T: 775-322-0626
info@natco.org
www.natco.org